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Stephan J.L. Bakker, MD, PhD,1 and Dorien M. Zelle, PhD1
Background.Posttransplantation diabetesmellitus (PTDM) is common in renal transplant recipients (RTR), increasing the risk of
graft failure, cardiovascular disease, and mortality. Early detection of a high risk for PTDM is warranted. Because liver function and
liver fat are involved, we investigated whether serum liver markers are associated with future PTDM in RTR.Methods.Between
2001 and 2003, 606 RTR with a functioning allograft beyond the first year after transplantation were included of which 500 partic-
ipants (56% men; age, 50 ± 12 years) were free of diabetes at baseline and had liver enzyme values (1 missing) available. Serum
concentrations of alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), alkaline phosphatase were measured at
baseline at 6.0 (6.2-11.5) years posttransplantation. PTDM cases were recorded until April 2012. Results. During median
follow-up for 9.6 years (interquartile range [IQR], 6.2-10.2) beyond baseline, 76 (15.2%) patients developed PTDM. Comparing
the highest to the lower tertiles, higher liver enzyme activities were significantly related to incident PTDM for ALT (hazard ratio
[HR], 2.22; IQR, 1.42-3.48), for GGT (HR, 2.93; IQR, 1.87-4.61), and for alkaline phosphatase (HR, 1.78; IQR, 1.13-2.80).
The associations of ALT and GGTwith development of PTDM were independent of potential confounders and risk factors,
including age, sex, renal function, medication use, lifestyle factors, adiposity, presence of the metabolic syndrome, fasting
glucose, HbA1c, proinsulin, and cytomegalovirus status. Conclusions. Markers for liver function and liver fat in the sub-
clinical range are potential markers for future PTDM, independent of other known risk factors. This may allow for early detec-
tion and management of PTDM development.
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Transplantation DIRECT ■ 2017Posttransplantation diabetes mellitus (PTDM), alsoknown as new-onset diabetes after transplantation1
is a common and serious metabolic complication after re-
nal transplantation. It places renal transplant recipients
(RTR) at increased risk of infections, graft failure, cardio-
vascular disease, and early mortality.2-4 To improve long-
term outcomes in RTR, it is of great importance to identify
modifiable risk factors for PTDM to effectively develop
strategies to reduce PTDM risk.
Although transplantation-specific risk factors for PTDM
are the chronic exposure to immunosuppressive medication
and cytomegalovirus (CMV) infection,5 PTDM and type 2
diabetes mellitus share similar pathophysiology. Compo-
nents of the metabolic syndrome, such as increased waist cir-
cumference, hyperlipidemia, and hypertension, enhance the
development of PTDM. The metabolic syndrome6 is very
common after renal transplantation, and partly explained
by the use of immunosuppressive medication and post
transplantation weight gain.7,8 In type 2 diabetes mellitus,
impaired liver function and liver fat play a role in the path-
ogenesis of PTDM.9-11 Liver enzymes like alanine amino-
transferase (ALT), gamma-glutamyl transferase (GGT),
and alkaline phosphatase (AP) are strongly related to impaired
cardiometabolic health and can be considered as markers for
the hepatic component of the metabolic syndrome. In RTR,
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© 2017 Wolters Kluwer Klaassen et al 3mortality, independent of the metabolic syndrome.12 To date
the association with liver enzymes and PTDM has not been
studied. Because the hepatic component of themetabolic syn-
drome can be an importantmodifiable risk factor for PTDM,
the present study prospectively investigates the association
between the liver enzymes ALT, GGT, andAP and PTDMde-
velopment after renal transplantation.
MATERIALS AND METHODS
Subjects
In this prospective cohort study, all adult RTR who sur-
vived with a functioning allograft beyond the first year after
transplantation were considered eligible to participate. Base-
line data, obtained at least 1 year after transplantation, were
collected between August 2001 and July 2003 at a median of
6.0 (interquartile range [IQR], 2.6-11.5) years after transplan-
tation.12 For the current study, 105 recipients with existing
diabetes (defined as fasting plasma glucose ≥ 7.0 and/or an-
tidiabetic medication) at baseline were excluded. All ethnici-
ties (3.6% non-white) were included. Baseline visits were
postponed until symptoms had resolved in patients with fe-
ver or other signs of infection (eg, complaints of upper respi-
ratory tract infection or urinary tract infection). Patients with
overt congestive heart failure and patients diagnosed with
cancer other than cured skin cancer were not considered eli-
gible for the study. Liver enzyme analyses were not available
for 1 patient resulting in a total of 500 patients for analysis.
The institutional review board approved the study protocol
(METc 2001/039). The study was performed per the declara-
tion of Helsinki and the declaration of Istanbul.
Endpoint of the Study
Care-based data about the development of PTDM after
baseline were retrieved from patient files of all RTR until
April 2012. PTDM was defined based on criteria outlined
by the International PTDM consensus guideline.13 PTDM
was defined as having a fasting plasma glucose level of
7.0 mmol/L or greater or use of oral hypoglycemic agents
or insulin therapy for 30 consecutive days or longer. HbA1c
was not included in the PDTM criteria because it is not rou-
tinely tested in nondiabetic RTR.
Measurements and Definitions
Patient characteristics including age, sex, date of trans-
plantation, and immunosuppressive medication were ex-
tracted from the Groningen Renal Transplant Database and
patients’medical records. Information on cardiovascular dis-
ease history, smoking, alcohol consumption, and physical ac-
tivity was obtained using a self-report questionnaire.14 At
baseline, body mass index (BMI) was calculated as weight
in kilograms, divided by height in meters squared. Hip cir-
cumference was measured at the widest point at the level of
the trochanter major, and waist circumference was measured
at the point halfway between the spina iliaca and the lower
rib using a plastic tape measure. Blood pressure was mea-
sured as the average of 3 automated measurements with
1-minute intervals after a 6-minute rest in supine position.
(Omron M4; Omron Europe B.V., the Netherlands). Blood
was drawn after an overnight fasting period. Serum creati-
nine concentrations were determined using the Jaffe method,
and serum triglycerides were determined with the glycerol-
3-phosphate oxidase-p-aminophenazone method. Totalcholesterol was determined using the CHOD PAP method
(MEGA AU 510; Merck Diagnostica, Darmstadt, Germany).
High-density lipoproteins (HDL) cholesterol was determined
with the CHOD PAP method on a Technikon RA-1000
(Bayer Diagnostics B.V., Mijdrecht, the Netherlands) and
low-density lipoproteins cholesterol was calculated using
the Friedewald formula.15 Plasma glucose was determined
by the glucose-oxidase method (YSI 2300 Stat plus; Yellow
Springs, OH). HbA1c was determined by high performance
liquid chromatography (VARIANT HbA1c Program with
Bio-Rad CARIANT Hb Testing System, Bio-Rad, Hercules,
CA) in all RTR at baseline for study purposes and at clinical
indication during follow-up. Serum high sensitive C-reactive
protein was assessedwith a high sensitivityC-reactive protein
enzyme-linked immunosorbent assay assay as described be-
fore.16 At baseline, uniform measurement of ALT, GGT,
and AP in serum was performed using IFCC-method
(37°C). Serum bone-specific AP kit was used for assessment
of the bone-specific part of AP activity (MetraTM Bone AP
assay (Quidel Corporation, San Diego, CA). Nonbone AP
was calculated by subtracting bone AP from total AP. Univer-
sity Medical Center Groningen laboratory ranges for the
liver enzymes are less than 45 U/L for ALT in men, less than
34 U/L for ALT in women, less than 55 U/L for GGT in men,
less than 38U/L for GGT inwomen, less than 115 U/L for AP
in men, and less than 98 for AP in women. Although aspar-
tate aminotransferase was measured too, it is not a candidate
marker for liver fat and was not related to PTDM in our
study (hazard ratio [HR], 1.46; 95% confidence interval
[CI], 0.92-2.33) nor in the literature,9 and therefore, it was
not further investigated. Homeostasis model assessment
was calculated as [glucose (in millimoles per liter)  insulin
(in microunits per milliliter)]/22.5.17,18 Metabolic syndrome
was defined according to theNational Cholesterol Education
Program Expert Panel, that is, presence of 3 or more of the
following components: waist circumference, greater than
102 cm in men and greater than 88 cm in women; serum tri-
glycerides, 1.70 mmol/L or greater; serum HDL cholesterol,
less than 1.03 mmol/L in men and less than 1.29 mmol/L in
women; blood pressure, 130/85 mm Hg or higher or use of
antihypertensive medication; and fasting plasma glucose,
6.1 mmol/L or greater or use of antidiabetic medication.
Statistical Analyses
Data were analyzed using SPSS version 22 (SPSS Inc.,
Chicago, IL), Stata IC version 11 (2009, StataCorp, College
Station, TX), and GraphPad Prism version 5.00 (GraphPad
Software, SanDiego,CA).Data are expressed asmean± stan-
dard deviation or as median (interquartile range) if not nor-
mally distributed. Baseline characteristics were compared
for sex-stratified tertiles of ALT, GGT, and AP. Categorical
variables were compared using χ2 test, and Kruskal-Wallis
1-way analysis of variance for continuous variables. The
association between liver enzymes and the development
of PTDM was analyzed using Kaplan-Meier analyses with
log-rank test. To rule out competing risk, a composite end-
point of the first occurrence of PTDM or death was studied
using sensitivity analysis. Finally, we tested for potential
nonlinearity of the associations of ALT, GGT, and AP with
PTDM using fractional polynomial regression analysis.19
To meet the proportionality of hazards assumption, the
first and second tertiles of liver enzymes were combined
4 Transplantation DIRECT ■ 2017 www.transplantationdirect.comand used as reference in the Cox-regression analyses. Mul-
tivariable Cox-regression analyses were applied to adjust
the association between ALT, GGT, bone AP and nonbone
AP with PTDM for age (model 2), which was also included
in models 3 to 8. We adjusted for kidney function (model 3),
use of immunosuppressive medication (model 4), lifestyle
factors (model 5), BMI, waist circumference, metabolic
syndrome (model 6), fasting glucose, HbA1c, proinsulin
(model 7), and CMV status (model 8).
Because sex-specific tertiles were used, no additional ad-
justment for sex was made. Patients were censored at date
of last follow-up or death.RESULTS
Baseline measurements were taken at a median (IQR) of
6.0 (2.6-11.5) years posttransplantation. The median (IQR)
baseline enzyme activities of ALT, GGT, and AP were 17.5
U/L (13.0-24.0 U/L), 22.0 U/L (17.0-36.0 U/L), and 70.0
U/L (56.3-88.8 U/L), respectively, with bone- and nonebone
AP, respectively, accounting for 42.9% ± 12% and
57.1% ± 12% of total AP activity. Patients with higher levels
of liver enzymes ALT, GGT, and AP more often had meta-
bolic syndrome at baseline (Table 1). When looking at the
individual components of the metabolic syndrome, higher
liver enzyme concentrations were associated mainly to higher
waist circumference and higher triglycerides. Associations
with HDL-cholesterol, fasting glucose, and systolic and
diastolic blood pressure were less clear. Although fasting
glucose and HbA1c were higher in the highest tertile of
GGT, no clear associations were found for ALT and AP.
Furthermore, patients with higher liver enzymes used
azathioprine less often, and creatinine clearance was
higher in the 2 highest tertiles of ALT.
During a follow-up time of 9.6 years (6.2-10.2) beyond
baseline, 76 subjects (15.2%) developed PTDM, and 137
RTR (27.4%) died. The cumulative incidence of PTDM atFIGURE 1. Kaplan-Meier curves for incident PTDM. Presence or absen
B), GGTand PTDM (panel C), total AP and PTDM (panel D).2, 4, 6, 8, and 10 years after baseline was 3.2, 5.6%, 8.4%,
13.4%, and 14.6%, respectively. Incidence of PTDM was
45 (16%) of 281 in men versus 31 (14%) of 219 in women.
RTR with metabolic syndrome at baseline were more likely
to develop PTDM (Figure 1A; HR, 3.77; 95% CI, 2.11-
6.74) than those without, with 62 cases (30.1%) versus 14
cases (6.8%), respectively (Figure 1A). The risk of PTDM
increased particularly in the highest tertiles of ALT, GGT,
and AP, whereas tertiles 1 and 2 were comparable for all
enzymes investigated (Figures 1B-D). In Cox-regression
analyses, GGTwas most strongly related to PTDM (Table 2).
Adjustment for age (model 2), and additional adjustments
for kidney function (model 3), immunosuppressive medication
(model 4), or lifestyle (model 5) did not materially influence
the association. Further adjustment for BMI, waist
circumference and presence of the metabolic syndrome
(model 6), fasting glucose, HbA1c, and proinsulin (model 7),
and CMV status (model 8) slightly weakened the
associations for ALT and GGT. Associations of total AP
with PTDM disappeared after adjustments applied in
models 6, 7, and 8, and of nonbone AP after adjustments
applied in models 6 and 7. Since AP is mostly produced in
the liver, as well as in other organs, but also in bone, we
analyzed bone- and nonebone AP separately. The nonbone
fraction of total AP showed a stronger association with
PTDM than the total AP, but was no longer associated to
PTDM after adjustment for BMI, waist circumference, and
metabolic syndrome (model 6), as well as for fasting glucose,
HbA1c, proinsulin (model 7).
Furthermore, ethnicity also did not change the associa-
tions of liver enzymes with incident PTDM.
Additionally, possible interactions between liver enzymes,
metabolic syndrome, and waist circumference were investi-
gated, but none were found. A slightly nonlinear pattern
was observed (Figures 2A-C). The figure illustrates how the
risk of PTDM can already be increased at liver enzyme
levels in the subclinical range.ce of metabolic syndrome and PTDM (panel A), ALTand PTDM (panel
TABLE 2.
Association of sex-stratified tertiles of ALT, GGT, total AP, and nonbone AP with incident PTDM
Reference




AP tertile 3 P
Model 1 (crude) 1.00 2.22 (1.42-3.48) 0.001 2.93 (1.87-4.61) <0.001 1.78 (1.13-2.80) 0.012 2.22 [1.40.3.43] 0.001
Model 2 (age) 1.00 2.21 [1.41-3.47] 0.001 2.94 [1.87-4.62] <0.001 1.79 (1.14-2.82) 0.012 2.21 [1.40-3.50] 0.001
Model 3 (renal function) 1.00 2.26 [1.43-3.57] <0.001 2.97 [1.88-4.69] <0.001 1.81 [1.15-2.85] 0.010 2.21 [1.40-3.49] 0.001
Model 4 (medication) 1.00 2.14 [1.36-3.37] 0.001 2.81 [1.78-4.45] <0.001 1.84 [1.15-2.93] 0.011 2.28 [1.44-3.63] <0.001
Model 5 (lifestyle) 1.00 2.50 [1.51-4.15] <0.001 2.90 [1.76-4.79] <0.001 1.99 [1.21-3.26] 0.007 2.54 [1.54-4.20] <0.001
Model 6 (BMI, waist circumference, M.S.) 1.00 1.74 [1.10-2.77] 0.018 2.08 [1.29-3.35] 0.003 1.28 [0.81-2.04] 0.292 1.51 [0.94-2.41] 0.089
Model 7 (fasting glucose, HbA1c, proinsulin) 1.00 1.87 (1.18-2.98) 0.008 2.56 [1.61-4.05] <0.001 1.53 [0.95-2.46] 0.077 1.35 [0.83-2.19] 0.230
Model 8 (CMV positive) 1.00 1.89 [1.11-3.23] 0.019 2.59 [1.52-4.41] <0.001 1.68 [0.98-2.86] 0.059 2.52 [1.47-4.33] 0.001
Model 1, univariate analysis.
Model 2, model 1+ adjusted for age.
Model 3, model 2+ creatinine clearance and proteinuria.
Model 4, model 2+ use of immunosuppressive medication (cyclosporine, tacrolimus, azathioprine, and daily prednisolone dose).
Model 5, model 2+ smoking, alcohol consumption, and physical activity.
Model 6, model 2+ BMI, waist circumference and presence of the metabolic syndrome.
Model 7, model 2+ fasting glucose, HbA1c, proinsulin.
Model 8, model 2+ CMV status.
Values are mean (95% CI).
© 2017 Wolters Kluwer Klaassen et al 5Median [IQR] steroid dose in subjects who developed
PTDM was no different from those who did not develop
PTDM (10.0 [7.5-10.0] vs 10.0 [7.5-10.0], respectively). OfFIGURE 2. Fractional polynomial graph of the hazard ratio for PTDM p
B) and total AP (panel C) in U/L.immunosuppressive calcineurin inhibitor drugs, use of
tacrolimus was significantly associated with development
of PTDM (HR, 1.82; 95% CI, 1.06-3.13; P = 0.029),er concentration serum concentrations of ALT (panel A), GGT (panel
6 Transplantation DIRECT ■ 2017 www.transplantationdirect.comindependent of age, sex and fasting glucose, whereas use of
cyclosporin was not independently associated (HR, 0.78;
95% CI, 0.49-1.23; P = 0.28).
Competing risk analyses using log2-tranformed concen-
trations of ALT, GGT, and AP revealed no competing risk
of mortality (crude ALT Cox HR, 1.70 [1.31-2.20] vs com-
peting risk HR, 1.82 [1.34-2.48]; crude GGT Cox HR,
1.48 [1.21-1.82] vs competing risk HR, 1.42 [1.10-1.82],
crude total AP Cox HR, 2.11 [1.39-3.20] vs competing risk
HR, 2.13 [1.36-3.34], crude nonbone AP Cox HR, 2.82
[1.28-6.21] vs competing risk HR, 3.03 [1.18-7.82]).DISCUSSION
This study shows that elevated serum concentrations in
the subclinical range of ALT and GGT and to lesser extent
AP were associated with incident PTDM in RTR, indepen-
dent of known risk factors for type 2 diabetes mellitus as
well as medication use. These data indicate that impaired
liver function is important already in the early stages of
PTDM pathogenesis.
Regarding the high prevalence of metabolic syndrome and
other mortality risk factors in our sample, it is possible that
deathmight prevent occurrence of PTDM.However, in com-
peting risk analyses, we found no competing risk of death for
ALT and total AP.
Regarding medication use, it could either mask the predic-
tive potential of the liver enzymes or the effect would be
stronger due to compromised liver function in this popula-
tion. However, the role of medication use seems minor,
whereas tacrolimus is related to future PTDM as expected
by its effect on reducing beta-cell insulin release.16,17 De-
spite the fact that use of tacrolimus was related to liver en-
zyme concentrations in our sample and that its use was
associated with development of PTDM, adjustment for
use of tacrolimus did not materially change associations
of liver enzymes with development of PTDM. Cyclospor-
ine is related to elevations in liver enzymes, but was not re-
lated to the development of type 2 diabetes in our study.
Thus, although medication may affect either liver enzyme
concentration or diabetes development, it does not alter
the role of liver function markers in PTDM development
in the present study.
Similarly, we found no evidence that CMV status alters the
role of liver function markers in PTDM development, except
for total AP.
Although levels of AP have been associated with cardio-
vascular disease andmortality, it has been less studied in rela-
tion to type 2 diabetes. It has been shown long ago that
nonbone AP can be elevated in patients with type 2 diabetes
mellitus.19 In the Mexico City diabetes study, it was shown
that elevated levels of total AP were related to future type 2
diabetes mellitus, but not independently of other predictors
of diabetes.20 Similarly, in the present study, total AP is re-
lated to future diabetes until adjusted for BMI, waist circum-
ference, and metabolic syndrome (model 6). The association
of total AP with future diabetes also lost significance when it
was adjusted for fasting glucose, HbA1c, and proinsulin
(model 7), and when it was adjusted for CMV status
(model 8). Findings were similar for nonbone AP, of which
the associations with future development of diabetes re-
mained significant in all models, except the model in whichthe association was adjusted for BMI, waist circumference,
and metabolic syndrome (model 6), and the model in which
the association was adjusted for fasting glucose, HbA1c, and
proinsulin (model 7). Bone AP was not associated with
PTDM. The pathway that is most likely underlying our study
outcomes is obesity driven as BMI and waist circumference
were markedly higher in the second and third tertile of ALT,
GGT, and AP suggesting an important role of abdominal
fat in deterioration of liver function. Weight gain is com-
mon after renal transplantation, particularly in the abdom-
inal region.8,21 Increased abdominal fat can enhance the
hepatic influx of free fatty acids, increasing hepatic fat stor-
age.22-25 Hepatic fat storage is associated with increased glu-
coneogenesis26 and increased hepatic insulin resistance27-29
as well as peripheral insulin resistance. Ultimately, this may
provoke β-cell insufficiency.30
The strength of this study is its prospective design, long du-
ration, and high completeness of follow-up. Information con-
cerning patient status was obtained by closely monitoring the
patients at regular check-ups at our clinic. Our study popula-
tion is a cross-section of all the RTR that visited our outpa-
tient clinic, giving a variation of RTR with different times
after transplantation, also including stable RTR late after
transplantation. This variation in time after transplantation
improves the generalizability to the total RTR population.
The fact that we have no data on liver fat imaging and on in-
sulin resistance may be considered limitation of our study.
Some degree of survivor bias at baseline may be present in
our study, because median time after transplantation is long.
Future studies could investigate whether liver enzymes also
predict PTDM earlier after transplantation, allowing earlier
intervention or prevention. Furthermore, liver enzymes were
only measured in the baseline samples. The use of a single
measurement of liver enzymesmay induce regression dilution
bias, thus it is possible that our results underestimated the
strength of the associations.31
Furthermore, the potential value of ALT, GGT, and AP
needs to be investigated for their predictive ability in other
centers and/or multicenter studies.
In summary, ALT and GGT in the subclinical range
were significantly associated with incident PTDM inde-
pendent of well-known risk factors. Importantly, the liver
enzymes were associated with BMI and waist circumfer-
ence, supporting the notion that the increased abdominal
fat causes hepatic fat accumulation, reducing hepatic in-
sulin sensitivity.27-29
The outcomes of our study have important implications
for posttransplantation care, because it shows that even mild
elevations in liver enzymes could reflect early impairments in
hepatic glucose metabolism because of hepatic fat accumula-
tion. Increased liver enzymes in RTR, particularly when
coexisting with increased waist circumference, should be
an incentive to target lifestyle factors, such as physical activity
and dietary habits to prevent or even reverse hepatic fat de-
position.32 Indeed, lifestyle interventions leading to a reduc-
tion in bodyweight and/or increased physical activity have
consistently shown to reduce liver fat and improve glucose
control.32–37 Another opportunity for management and pre-
vention of PTDM lies in the choice of the immunosuppres-
sive agents. Immunosuppressive regimens could be tailored
to the individual patient on the basis of predictive criteria
for the development of PTDM.
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